M-Life™ Uses Novel Algorithms to Identify Unique Atom Interactions within a Molecule Utilizing Deep Learning, Artificial Intelligence and Big/Small Data
The M-Life™ process begins with data-fusion wherein both quantitative and non-quantitative data associated with efficacy and adverse effects are fused. Molecular structures are transcribed to an energy-density analog. Algorithmic assessment is accomplished via M-Life’s P2L™ (Pattern-to-Lead) platform. MiST™ aggregate’s all molecular modalities (the independent pattern’s associated efficacy and toxicity), building a composited representation of attributes similar to image tomography.
See Highlights or for More Information click the “Access Portal” Button Below:
Access Portal
Press Releases
COVID-19 Drug Repurposing Program
M-Life™ Drugs on Market as Repurposing Prospects for the Treatment of COVID-19
M-Life™ Toxicity Predictions for Repurposed COVID-19 Drugs
https://www.biospace.com/article/m-life-releases-toxicity-predictions-for-covid-19-drugs/
M-Life™ COVID-19 Cytokine Storm Repurposing Possibilities
M-Life™ Novel IL-6 Molecules and Efficacy/Toxicity Data
Discovery Programs
The Company currently has active programs in three target areas: (a) the development of new drugs (b) agricultural chemicals (herbicides and insecticides) (c) industrial chemicals. Eight drug/medication programs comprise current development efforts in broad variety of therapeutic classes including analgesics, IL-6 inhibition, antibiotics and anticancer drugs. Agricultural chemical programs include both insecticides and herbicides, the latter primarily aimed at a new effective, non-toxic replacement for Roundup™ (glyphosate). Present industrial chemical development efforts tightly focus on the design of fluorescent molecules (fluorophores) wherein design, synthesis and testing have been completed.
Cancer Therapeutics
The Company’s current efforts center on the design of both new multi-targeting-agents (MTA’s), or chimeras, as well as the advancement of M-Life™ licensed tubulin targeting molecules for use in the treatment of pediatric Acute Myeloid Leukemia (AML). M-Life™ programs leverage the published works of Dr. Peter Crooks, M-Life Chief Discovery Officer and M-Life’s proprietary design platforms. The initial commercialization strategy is to advance the licensed tubulin molecules novel chimera molecules through IND. Once significant advancement of these molecules is made through the FDA approval process, therapeutic applicability will be expanded to include CNS and many other types of cancer.
M-Life™ Cancer Therapeutics Deck
Presentation M-Life Angel Investor CDN
M-Life™ Cancer Therapeutics Technical Overview
M-Life Technical Summary July 2021 CDN Holders
Company Leadership
The Team is composed of innovators and pioneers in the underlaying fields of M-Life’s™ technology. These fields include chemistry, chem-bioinformatics, biology, translational medicine, advanced mathematics, computer science, engineering, and physics. The Team holds patents and/or published seminal works on pattern recognition, molecule design, molecular synthesis, artificial intelligence, machine learning, advanced data structures, bio-informatics, toxicology, biology, target & phenotypical based discovery, proteomics, genomics as applied the development of new drugs, diagnostics, pathogen detection, molecular discovery, telecommunications, image processing and other technologies.-click photo of Team Member for additional information-
Ted Moskal
President, CEO and Founder
Kai Lo, MBA
Chief Financial Officer
John Panos, Ph.D
Director of Translational Discovery
Peter Crooks, M.Sc., Ph.D., D.Sc.
Chief Discovery Officer
Jon Wilkes, Ph.D.
Chief Scientist
Chris Bojrab, MD.
Chief Medical Officer
The M-Life™ Molecule Intellectual Property Portfolio
-
- Provisional Patent Applications 62/927,744 and 62/947,031
- US Pat. No. 9,597,316, US Pat. No. 9,884,842, US Pat. No. 10,100,029, US Pat. No. 9,938,246
and US Pat. No. 10,239,844 - Various In-work Provisional Patent Applications for molecules in multiple therapeutic classes
